Lineage Cell Therapeutics, Inc. (LCTX)
NYSEAMERICAN: LCTX · Real-Time Price · USD
0.4823
-0.0160 (-3.21%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Lineage Cell Therapeutics Employees
As of December 31, 2024, Lineage Cell Therapeutics had 77 total employees, including 70 full-time and 7 part-time employees. The number of employees increased by 2 or 2.67% compared to the previous year.
Employees
77
Change (1Y)
2
Growth (1Y)
2.67%
Revenue / Employee
$123,364
Profits / Employee
-$241,675
Market Cap
111.89M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
LCTX News
- 5 days ago - Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 3rd Annual Spinal Cord Injury Investor Symposium - Business Wire
- 6 days ago - Lineage to Present at 2025 Eyecelerator Meeting Sponsored by the American Academy of Ophthalmology (AAO) - Business Wire
- 6 weeks ago - Lineage Cell Therapeutics, Inc. (LCTX) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - Business Wire
- 7 weeks ago - Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025 - Business Wire
- 2 months ago - Lineage Initiates Clinical Study of OPC1 for Spinal Cord Injury - Business Wire
- 2 months ago - Lineage Cell Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Lifesciences Conference - Business Wire
- 3 months ago - Lineage Cell Therapeutics Announces Closing of Second Tranche of Previously Announced Registered Direct Offering - Business Wire